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Abstract
Background: Whole-brain radiation therapy (WBRT) with hippocampus sparing (HS) has been investigated by the
radiation oncology working group (RTOG) 0933 trial for patients with multiple brain metastases. They showed a
decrease of adverse neurocognitive effects with HS WBRT compared to WBRT alone. With the development of
automated treatment planning system (aTPS) in the last years, a standardization of the plan quality at a high level
was achieved. The goal of this study was to evaluate the feasibility of using an aTPS for the treatment of HS WBRT
and see if the RTOG 0933 dose constraints could be achieved and improved.
Methods: Ten consecutive patients treated with HS WBRT were enrolled in this study. 10 × 3 Gy was prescribed
according to the RTOG 0933 protocol to 92% of the target volume (whole-brain excluding the hippocampus
expanded by 5 mm in 3-dimensions). In contrast to RTOG 0933, the maximum allowed point dose to normal brain
was significantly lowered and restricted to 36.5 Gy. All patients were planned with volumetric modulated arc
therapy (VMAT) technique using four arcs. Plans were optimized using Auto-Planning (AP) (Philips Radiation
Oncology Systems) with one single AP template and optimization.
Results: All the constraints from the RTOG 0933 trial were achieved. A significant improvement for the maximal
dose to 2% of the brain with a reduction of 4 Gy was achieved (33.5 Gy vs. RTOG 37.5 Gy) and the minimum
hippocampus dose was reduced by 10% (8.1 Gy vs. RTOG 9 Gy). A steep dose gradient around the hippocampus
was achieved with a mean dose of 27.3 Gy at a distance between 0.5 cm and 1 cm from the hippocampus. The
effective working time to optimize a plan was kept below 6′.
Conclusion: Automated treatment planning for HS WBRT was able to fulfil all the recommendations from the
RTOG 0933 study while significantly improving dose homogeneity and decreasing unnecessary hot spot in the
normal brain. With this approach, a standardization of plan quality was achieved and the effective time required for
plan optimization was minimized.
Keywords: Volumetric modulated arc therapy, Automated planning optimization, Whole brain irradiation,
Hippocampus sparing, RTOG 0933
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Background
Whole-brain radiation therapy (WBRT) was for de-
cades the standard treatment for patient with multiple
brain metastases [1] by various malignancies or for
prophylactic cranial irradiation for patients with small
cell lung carcinoma. However, the use of WBRT has
decreased in the past years due to reports on possible
equivalence of an SRS only approach, the advent of
targeted therapies with CNS activity [2, 3] and the
recognition of adverse neurocognitive effects from
WBRT which are believed to be caused from the
damage to the hippocampus due to irradiation [4].
With the improvement of radiation therapy (RT) de-
livery such as intensity modulated radio-therapy
(IMRT) or volumetric modulated radiotherapy
(VMAT), the concept of hippocampal sparing WBRT
has been proposed and investigated with the hypoth-
esis to avoid some of the observed neurocognitive
toxicity of conventional WBRT [1].
The hippocampus sparring (HS) is aimed at, but a suf-
ficient dose is required to the remaining brain tissue to
avoid the risk of marginal failure in the HS dose gradi-
ent. Reassuringly, several reports have shown that the
risk of metastases occurring in the hippocampal area is
low [5]. Currently, HS-WBRT is also evaluated using in
addition a simultaneous integrated boost to increase the
probability of local control in macroscopic disease [6, 7].
Recently, HS WBRT for brain metastases has been
evaluated in a prospective phase II study (RTOG 0933)
[8]. The primary objective was the assessment of the de-
layed recall by the Hopkins Verbal Learning Test-
Revised 4 (HVLT-R) [8]. The results were positive show-
ing no decline in HVLT-R at two and four months and
no change in respect to the quality of life in comparison
to the historical control group (WBRT) in patients still
alive at 6 months [9]. Strict constraints to the target
coverage as well as the dose to the organs at risk (OAR)
were defined in the radiation oncology working group
(RTOG) 0933 protocol. Nevertheless, to achieve a rea-
sonable dose gradient to spare the hippocampus, high
doses to the PTV, i.e. the normal brain, were allowed:
not more than 2% of the PTV was recommended to re-
ceive a cumulative dose of 37.5 Gy and 40 Gy was still
allowed. Automated treatment planning system (aTPS)
have gained attention, as they may allow an automation
of the optimization process leading to a standardization
of the plan quality at a high level, surpassing in some
cases the manually optimized plans [10–12].
The goal of this study was to evaluate the feasibility of
using an automated treatment planning system (aTPS)
for the treatment of HS WBRT to achieve a) consistent
planer-independent plan quality and b) to significantly
reduce the high dose to normal brain while still achiev-
ing all RTOG 0933 dose constraints.
Methods and materials
Automatic VMAT optimization
The automated treatment planning module, Auto-
Planning (AP), included in Pinnacle 14.0 (Philips Radi-
ation Oncology Systems, Fitchburg, WI) was used for plan
optimization. It is a fully integrated module in the TPS,
similar to the “manual” inverse optimizer module and has
been previously described [10, 13]. Briefly, Pinnacle AP is
a template-knowledge based treatment planning system.
During AP, the optimizer automatically runs multiple
times with the individual optimization goals, constraints
and weights automatically added and adjusts the priority
of clinical goals based on their probability of being
achieved. A collapsed cone convolution algorithm was
used to calculate the dose distribution (version 14.0).
Ethics approval and patient selection
All patients included in this study have given their ap-
proval to use their data for scientific research. For this
treatment planning study, ten consecutive patients
treated for HS WBRT were enrolled.
Structure definition
Computer tomography and magnetic resonance imaging
were registered and fused. These images were used for the
delineation of the hippocampus, eyes, lens, lacrimal glands
and whole brain. The planning target volume (PTV) was
defined as the whole-brain expanded by 5 mm in three di-
mensions excluding the hippocampal avoidance regions as
recommended in the RTOG 0933 protocol. The hippo-
campal avoidance regions were defined as the hippocam-
pal expanded by 5 mm in three dimensions.
VMAT optimization using an automated treatment
planning system
The plan optimization was automated using AP where
the clinical objectives and priorities for each PTV and
OAR were defined. The model created in Auto-Planning
was optimized based on two cases to achieve or improve
all recommended constraints from RTOG 0933 protocol,
see Table 1. These two cases were not included in the
set of patients used for the plan evaluation.
All patients were planned with a VMAT technique
using four arcs: two 360° co-planar arcs, and two non-
coplanar arcs with couch at 300° and 60° with arcs ran-
ging from 181° to 10° moving clockwise and 350° to 179°
moving clockwise. The plans were optimized for a Tril-
ogy Linac (Varian Medical System, Palo Alto, CA) with a
60 pair multileaf collimator (MLC) of 5 mm width (Mil-
lennium MLC).
One treatment plan was generated for each patient
using AP and only one optimization cycle was per-
formed. The plan parameters used for the optimization
are listed in Table 2. For optimization purposes, a target
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help structure (PTV_7mm), defined as the PTV minus
the hippocampus expanded by 7 mm in three-dimension
in order to allow the optimizer to fulfil all the objectives.
This structure was used only for optimization purposes,
see Table 2, and not for the plan normalization. This was
the only help structure generated for the optimization
step. 10 × 3 Gy was prescribed to 92% of the PTV.
Quality assurance for each of the ten clinical AP plans
was performed on a phantom (Delta4, ScandiDos AB,
Uppsala, Sweden). All fields had to have a gamma value
>95% with a distance to agreement of 3 mm and a dose
difference of 3%.
Plan evaluation
Dose–volume histograms (DVH) were calculated for the
PTVs and OARs of each plan. All plans were normalized
to 92% of the PTV volume (V92%) receiving 30 Gy.
Plan results were compared to published DVH param-
eters for HS WBRT [1, 14, 15]. For the PTV, dose to 2%
(D2%) and 98% (D98%), homogeneity index (HI) defined
as (D2%-D98%)/Dmedian, and percent of the target vol-
ume receiving 95% of the prescribed dose (V95%) were
evaluated. The hippocampus dose was evaluated based
on its minimal dose (D100%), maximal dose (Dmax) and
mean 2Gy equivalent dose calculated with an α/β ratio
of 2 Gy. The other OARs, lens, lacrimal glands, optic
chiasm and optical nerve were evaluated based on the
maximal point dose.
Four ring structures around the hippocampus were
generated in order to evaluate the dose gradient between
the hippocampus and the target. The first ring was gen-
erated by applying a margin of 5 mm to the hippocam-
pus in 3-dimensions. The second, third and fourth ring
was defined as an outer margin of 5 mm in 3-
dimensions to the first, second and third ring
Table 1 Dose volume histogram, monitor units and treatment time for hippocampus sparing whole brain irradiation
HS WBRT
Krayenbuehl et al.
Mean (range)
RTOG 0933 recommendation Gondi et al.
Mean (range)
Nevelsky et al.
Mean (range)
Wang et al.
Mean (range)
PTV D98% (Gy) 25.8 (25.0–27.1) ≥ 25Gy N/A 25.7 (25.4–25.9)
PTV V95% (%) 96.4 (95.2–97.8) N/A 96.9 (96.1–97.5) N/A 96.9 (96.0–97.5)
PTV D2 (Gy) 33.5 (32.8–34.6) ≤37.5 N/A 37.2 (36.9–37.6) 35.1 (34.8–35.6)
PTV Dmax (Gy) 36 (35.1–36.5) N/A N/A N/A N/A
PTV V30Gy (%) 92 (92.0–92.0) = 90 N/A 92.1 (90.5–93.2) N/A
PTV HI 0.24 (0.21–0.26) N/A 0.3 (0.26–0.34) 0.36 (0.34–0.37) 0.26 (0.23–0.33)
PTV Dmean (Gy) 31.5 (30.9–32.2) N/A N/A N/A N/A
HC D100% (Gy) 8.1 (7.8–8.5) ≤ 9 N/A 8.4 (7.7–8.9) 9.3 (8.3–10.0)
HC Dmean (Gy2) 7.3 (6.0–7.9) N/A 7.3 (7.2–7.6) N/A N/A
HC Dmax (Gy) 14.1 (12.0–15.3) ≤ 16 15.3 (14.3–15.9) 14.3 (13.5–15.4) 16 (14.6–16.9)
Lens Dmax (Gy) 4.6 (3.7–5.6) N/A 3.8 (3.1–4.3) N/A 5.8 (4.5–6.5)
Opt chiasm Dmax (Gy) 32.9 (31.7–35.1) ≤ 37.5 N/A 36.2 (33.9–37.2) 34.7 (33.1–36.8)
Opt nerve Dmax (Gy) 33.1 (32.5–33.8) ≤ 37.5 N/A 32.5 (28.3–35.7) 32.0 (23.7–36.1)
Lacrymal glands Dmax (Gy) 10.8 (6.6–15.5) ≤ 37.5 N/A N/A N/A
MU 1481 (1345–1550) N/A N/A 1724 (1622–1914) N/A
Effective working time (min) 4.5 (4.1–5.3) N/A N/A N/A N/A
Abbreviations: PTV: planning target volume, D98%: dose to 98% of the volume, V95%: volume covered by 95% of the prescribed dose, D2%: dose to 2% of the
volume, Dmax: maximal point dose, V30Gy: volume covered by 95% of the prescribed dose, HI: homogeneity index, HC: hippocampus, MU: monitor units, Gy2:
equivalent dose if the actual treatment was delivered in 2 Gy per fraction with an α/β ratio of 2 Gy, MU: monitor units
Table 2 Dose constraints for plan optimization and tuning
balance
Structure DVH parameter Dose (Gy) Priority
PTV_7mm – 30 –
Hippocampus Max dose 14.5 High
D40% 10 Medium
D99% 8 High
Lens Max dose 5 High
Lacrimal gland Max dose 20 Medium
Mean dose 10 Medium
Tuning balance
Conform to Target: 30%
Dose fall-off Margin: 2.6 cm
Hot-Spot Maximum goal: 105%
Abbreviations: PTV_7mm planning target volume minus the hippocampus
expanded by 7 mm in three-dimension, D99% dose to 99% of the volume,
D40% dose to 40% of the volume
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respectively, see Fig. 1. The minimal, maximal and mean
dose to these ring structures were evaluated.
In addition to the DVH parameter evaluation, the
planning time and the number of monitor units (MU)
were reported and evaluated. The planning time was de-
fined as the effective working time starting when the tar-
get and OAR volumes are defined by the clinicians and
finishing when the plans were optimized by a
dosimetrist.
Results
Target and OAR objectives and priorities used for the
optimization of HS WBRT with AP are listed in Table 2.
These settings were used for the optimization of all cases
planned with Auto-Planning. No individual optimization
was performed. The plans were normalized to 92% of
the target volume receiving 30Gy. The target was de-
fined as the brain subtracted by the hippocampal ex-
panded by 5 mm in three-dimension.
Target volumes
D2% and D98% of the target volume were 33.1 Gy ran-
ging from 32.6 Gy to 33.6 Gy and 25.8 Gy ranging from
25.0 Gy to 27.8 Gy respectively, fulfilling and even sur-
passing significantly the RTOG 0933 constraints. The
target mean dose was 31.5 Gy ranging from 30.9 Gy to
32.2 Gy. The homogeneity index was 0.24 ranging from
0.21 to 0.26. The volume covered by 95% of the pre-
scribed dose was larger than 95.2% for every patient with
a mean value of 96.4%. The maximal point for every plan
was kept below 36.5 Gy.
The dose in the ring structures around the hippocam-
pus are displayed in Fig. 2. The mean dose within 5 mm
to the hippocampus was 16.8 Gy with a minimal dose of
8.8 Gy and a maximal dose of 27.2 Gy. The mean dose
increased to 27.3 Gy, 31.0 Gy and 31.7Gy in the second
third and fourth ring respectively.
Organs at risk
The OAR doses are summarized in Table 1. AP was able
to achieve all of the RTOG 0933 constraints. The mean
D100% to the hippocampus was 8.1 Gy ranging from
7.8 Gy to 8.5 Gy and the mean 2Gy equivalent dose was
7.3 Gy ranging from 6.0 Gy to 7.6 Gy.
The mean maximal dose to the optical nerve was
33.1 Gy ranging from 32.5Gy to 33.8 Gy and the max-
imal dose for the lacrimal glands was always kept bellow
15.5 Gy, far below the recommended of 37.5 Gy dose
from the RTOG 0933. The maximal dose to the optic
chiasm was kept below 35.1 Gy for every cases, below
the recommendation of 37.5Gy from RTOG protocol.
Planning time and monitor units
The working planning time, defined as the effective
working time to generate a plan was kept below 6 min
for each plan optimized. The average time was 4.5’ ran-
ging from 4.1’ to 5.3’. The mean MU was 1481 MU ran-
ging from 1448 MU to 1554 MU.
The DVH averaged over the ten cases planned with
HS WBRT are plotted in Fig. 3. The DVH parameters,
monitor units and effective working time to optimize a
HS WBRT plan are summarized in Table 1. A typical
dose distribution for HS WBRT in axial, coronal and sa-
gittal view are displayed on Fig. 4.
Discussion
HS WBRT has gained much attention as an attractive
concept and RTOG 0933 was a significant achievement to
show a clinical relevant benefit of this approach. However,
plan optimization of HS WBRT is a complex process,
where hard constraints have to be fulfilled. A compromise
between minimal dose to the hippocampus, target cover-
age and maximal dose to the target needs to be achieved.
Multiple iterations are normally required before all the
constraints are fulfilled. After each iteration, the planner
has to modify the constraints, generate new help struc-
tures to take into account the cold and hot spots until a
satisfactory dose distribution is achieved.
Our hypothesis was that with an automated planning
approach a) all these complex planning steps could be
automated resulting in a reduction of the effective
Fig. 1 Ring structures around the hippocampus. The hippocampus
is segmented in orange, the target in red and the first, second, third
and fourth ring structures in light blue, blue, dark blue and violet
respectively. All the ring structures have a width of 5 mm
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working time [10], b) a reproducible high quality dose
distribution can be achieved independent of the planner
experience and c) volumes of normal brain receiving
hotspots higher than 115% can be avoided.
The effective working time for plan optimization for
automated planning of HS WBRT was in the order of
five minutes. Beside the reduction of working time re-
quired to generate a plan for HS WBRT, an improve-
ment of the average plan quality was achieved. Indeed,
all the RTOG constraints were easily fulfilled after a sin-
gle optimization. The two main improvements in the
plan quality were a reduction of the hippocampus min-
imal dose by 10% and a reduction of the D2% for the
target from 125 to 112% without compromising PTV
coverage required within RTOG 0933. We consider es-
pecially the latter an achievement, i.e. significantly less
high dose within the normal brain (2% normal brain re-
ceiving 33.5Gy compared to 37.2 Gy and 37.5 Gy (8, 14)
the most relevant finding for clinical practice.
In the study performed by Gondi et al., for HS WBRT,
using linac-based IMRT fields, 30Gy was prescribed in
ten fractions [1]. They reported a maximum dose of
15.3 Gy and a medium dose of 7.8 Gy to the hippocam-
pus. D2% to the brain was not reported but dose larger
than 40 Gy (133% of the prescribed dose) were displayed
on the DVH, see Table 1. The plan optimization was
done with nine non-coplanar IMRT fields using seven
different couch angles. With such a beam arrangement,
one can assume that the treatment delivery would be
time consuming.
In the study performed by Nevelsky et al. using a
linac-based IMRT nine fields, only two different couch
angles were used in order to reduce the treatment deliv-
ery time [14]. They were able to reduce the maximal
dose to the hippocampus compared to Gondi et al. to
14.3 Gy, see Table 1. A mean minimal dose of 8.4 Gy to
the hippocampus was reported. These values are very
similar to our results were a value of 14.1 Gy and 8.1 Gy
for maximal and minimal dose were obtained. The D2%
to the brain achieved by Nelesky et al. was 37.2 Gy
(124% of the prescribed dose), close to the maximal rec-
ommended value from the RTOG protocol of 37.5 Gy
Fig. 2 Dose in close proximity to the hippocampus. Abbreviations: Dmin: Minimal dose, Dmean: Mean dose, Dmax: Maximal dose
Fig. 3 Average dose volume histogram over ten patients planned with HS WBRT
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and an HI of 0.36 was achieved. In our study the D2%
and the HI were both significantly improved. This led to
an improvement of the dose homogeneity and a reduc-
tion of hot spot in the brain.
In order to reduce further the treatment delivery,
Wang et al. [15] evaluated an automated treatment plan-
ning system using two coplanar arcs. Eight of the ten pa-
tients had a minimal and maximal hippocampus dose
above the recommended value from the RTOG 0933
protocol. There D2% to the PTV was 35.1Gy, below the
37.5Gy recommended values from the protocol. In the
current study, four arcs were used which allowed to de-
crease furthermore the D2% by 1.6Gy and fulfil all the
recommended constraints from the RTOG 0933 proto-
col. The increase of arcs will have an impact on the
treatment delivery time.
In the RTOG 0933, 98% of the target volume should
receive at least 25Gy in order to avoid cold spot in the
brain which could lead to an increase of the local relapse
(LR). The brain region receiving the lowest dose is in
close proximity to the hippocampus avoidance region.
By under-dosing this region, an increase of LR compared
to WBRT alone could occur [5]. The LR could increase
up to 4% for small-cell lung cancer (SCLC). Therefore, a
special attention was taken when choosing the
optimization parameters to achieve a high dose gradient
around the hippocampus. At a distance from 0.5 cm to
1 cm from the hippocampus, i.e. in the first 5 mm from
the hippocampus avoidance region, the mean dose was
27.3 Gy, close to the prescribed dose of 30 Gy.
However, to arrive at an acceptable hippocampus sparing,
the PTV constraints developed by Gondi et al. were incor-
porated into RTOG 0933 and this allowed significant hot-
spots within the normal brain: D2% was set to 40 Gy
allowing normal brain to have hotspots up to 133% of the
prescribed dose. Although restricting hippocampal dose has
been proven to protect neurocognitive function early, i.e.
4 months, after HS WBRT, its benefits at later time points
are not yet known. In contrast, several reports have shown
cortical changes like cortical thinning and microvascular
perfusion changes after radiotherapy which may counteract
initial protective effects on hippocampal function and may
negatively affect neurocognitive functions other than those
mediated by proper hippocampal function [16, 17].
Conclusion
With automated treatment planning, a standardization
of the plan quality was achieved and the effective time
required for planning optimization was kept close to five
minutes. aTPS for HS WBRT was able to fulfil all the
recommendations from the RTOG 0933 study. Further-
more, the dose to most of the organs at risk could be
significantly reduced, there was an improvement in dose
homogeneity and a highly clinical relevant decrease of
hot spots within the normal brain could be achieved.
Abbreviations
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Fig. 4 Dose distribution in axial, coronal and sagittal view for a patient planned with HS WBRT with 10 × 3 Gy
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